Search

Your search keyword '"Hao Huai"' showing total 278 results
Start Over Author "Hao Huai"
278 results on '"Hao Huai"'

1. Transcriptomics and metabolomics revealed the molecular basis of the color formation in the roots of Panax notoginseng

Author

Kang Ning, Hao Huai, Mengzhi Li, Yuli Xu, Fugang Wei, Zhongjian Chen, Yong Wang, Pengcheng Huang, Yuqi Yu, Shilin Chen, and Linlin Dong

Subjects
Panax notoginseng, Anthocyanin, Metabolome, Full-length transcriptome, R2R3-MYB, Science (General), Q1-390, Social sciences (General), H1-99
Abstract

Panax notoginseng is a traditional Chinese medicine rich in many pharmacological components. The root of the ‘Miaoxiang Sanqi No. 2’ is yellow or greenish yellow, while a novel cultivar-‘Wenyuan Ziqi No. 1’ shows purple root and is thought to have high medicinal value. Little information is available about the anthocyanin biosynthesis in P. notoginseng root. In this study, we compared the ‘Miaoxiang Sanqi No. 2’ and ‘Wenyuan Ziqi No. 1’ in morphological, transcriptional and metabolic levels. The results showed that purple rich in the periderm, rhizome and phloem around cambium of the ‘Wenyuan Ziqi No. 1’ root and cyanidin 3-O-galactoside was the main anthocyanin causing purple. Moreover, ‘Wenyuan Ziqi No. 1’ highly accumulated in 155 metabolites, including flavones, phenylpropanoids and lipids. Transcriptome data showed that phenylpropanoid biosynthesis pathway genes are highly expressed in ‘Wenyuan Ziqi No. 1’. Conjoint analysis showed that anthocyanin biosynthesis pathway substances were highly accumulated in ‘Wenyuan Ziqi No. 1’, and the expression level of structural genes involved in anthocyanin biosynthesis pathway was higher in ‘Wenyuan Ziqi No. 1’. Meanwhile, eight R2R3-MYB genes that might be involved in anthocyanin biosynthesis were identified. The comprehensive analysis of two cultivars provides new insights into the understanding of root coloration in P. notoginseng.

Published
2024
Full Text
View/download PDF

2. Genomic and Transcriptomic Analysis Provide Insights Into Root Rot Resistance in Panax notoginseng

Author

Kang Ning, Mengzhi Li, Guangfei Wei, Yuxin Zhou, Guozhuang Zhang, Hao Huai, Fugang Wei, Zhongjian Chen, Yong Wang, Linlin Dong, and Shilin Chen

Subjects
P. notoginseng, biotic stress, root rot, WGCNA, WRKY, Plant culture, SB1-1110
Abstract

Panax notoginseng (Panax notoginseng (Burk.) F.H. Chen), a plant of high medicinal value, is severely affected by root rot during cultivation. Here, we generated a reference genome of P. notoginseng, with a contig N50 size of 241.268 kb, and identified 66 disease-resistance genes (R-genes) as candidate genes for breeding disease-resistant varieties. We then investigated the molecular mechanism underlying the responses of resistant and susceptible P. notoginseng genotypes to Fusarium oxysporum infection at six time points by RNA-seq. Functional analysis of the genes differentially expressed between the two genotypes indicated that genes involved in the defense response biological process like hormone transduction and plant-pathogen interaction are continuously and highly expressed in resistant genotype during infection. Moreover, salicylic acid and jasmonic acid levels gradually increased during infection in the resistant genotype. Coexpression analysis showed that PnWRKY22 acts as a hub gene in the defense response of the resistant genotype. Finally, transiently overexpressing PnWRKY22 increased salicylic acid levels in P. notoginseng leaves. Our findings provide a theoretical basis for studying root rot resistance in P. notoginseng.

Published
2021
Full Text
View/download PDF

6. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment

Author

Delord, Jean-Pierre, Argilés, Guillem, Fayette, Jerôme, Wirth, Lori, Kasper, Stefan, Siena, Salvatore, Mesia, Ricard, Berardi, Rossana, Cervantes, Andrés, Dekervel, Jeroen, Zhao, Sylvia, Sun, Yongjian, Hao, Huai-Xiang, Tiedt, Ralph, Vicente, Sergio, Myers, Andrea, and Siu, Lillian L.

Published
2020
Full Text
View/download PDF

8. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms

Author

Wang, Ye, Mohseni, Morvarid, Grauel, Angelo, Diez, Javier Estrada, Guan, Wei, Liang, Simon, Choi, Jiyoung Elizabeth, Pu, Minying, Chen, Dongshu, Laszewski, Tyler, Schwartz, Stephanie, Gu, Jane, Mansur, Leandra, Burks, Tyler, Brodeur, Lauren, Velazquez, Roberto, Kovats, Steve, Pant, Bhavesh, Buruzula, Giri, Deng, Emily, Chen, Julie T., Sari-Sarraf, Farid, Dornelas, Christina, Varadarajan, Malini, Yu, Haiyan, Liu, Chen, Lim, Joanne, Hao, Huai-Xiang, Jiang, Xiaomo, Malamas, Anthony, LaMarche, Matthew J., Geyer, Felipe Correa, McLaughlin, Margaret, Costa, Carlotta, Wagner, Joel, Ruddy, David, Jayaraman, Pushpa, Kirkpatrick, Nathaniel D., Zhang, Pu, Iartchouk, Oleg, Aardalen, Kimberly, Cremasco, Viviana, Dranoff, Glenn, Engelman, Jeffrey A., Silver, Serena, Wang, Hongyun, Hastings, William D., and Goldoni, Silvia

Published
2021
Full Text
View/download PDF

11. Supplementary Figure 3 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Author

Huynh, Hung, primary, Hao, Huai-Xiang, primary, Chan, Stephen L., primary, Chen, David, primary, Ong, Richard, primary, Soo, Khee Chee, primary, Pochanard, Panisa, primary, Yang, David, primary, Ruddy, David, primary, Liu, Manway, primary, Derti, Adnan, primary, Balak, Marissa N., primary, Palmer, Michael R., primary, Wang, Yan, primary, Lee, Benjamin H., primary, Sellami, Dalila, primary, Zhu, Andrew X., primary, Schlegel, Robert, primary, and Huang, Alan, primary

Published
2023
Full Text
View/download PDF

12. Table S3 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Author

Hao, Huai-Xiang, primary, Wang, Hongyun, primary, Liu, Chen, primary, Kovats, Steven, primary, Velazquez, Roberto, primary, Lu, Hengyu, primary, Pant, Bhavesh, primary, Shirley, Matthew, primary, Meyer, Matthew J., primary, Pu, Minying, primary, Lim, Joanne, primary, Fleming, Michael, primary, Alexander, LeighAnn, primary, Farsidjani, Ali, primary, LaMarche, Matthew J., primary, Moody, Susan, primary, Silver, Serena J., primary, Caponigro, Giordano, primary, Stuart, Darrin D., primary, Abrams, Tinya J., primary, Hammerman, Peter S., primary, Williams, Juliet, primary, Engelman, Jeffrey A., primary, Goldoni, Silvia, primary, and Mohseni, Morvarid, primary

Published
2023
Full Text
View/download PDF

13. Fig S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Author

Hao, Huai-Xiang, primary, Wang, Hongyun, primary, Liu, Chen, primary, Kovats, Steven, primary, Velazquez, Roberto, primary, Lu, Hengyu, primary, Pant, Bhavesh, primary, Shirley, Matthew, primary, Meyer, Matthew J., primary, Pu, Minying, primary, Lim, Joanne, primary, Fleming, Michael, primary, Alexander, LeighAnn, primary, Farsidjani, Ali, primary, LaMarche, Matthew J., primary, Moody, Susan, primary, Silver, Serena J., primary, Caponigro, Giordano, primary, Stuart, Darrin D., primary, Abrams, Tinya J., primary, Hammerman, Peter S., primary, Williams, Juliet, primary, Engelman, Jeffrey A., primary, Goldoni, Silvia, primary, and Mohseni, Morvarid, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure Legends, Tables 1 - 3 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Author

Huynh, Hung, primary, Hao, Huai-Xiang, primary, Chan, Stephen L., primary, Chen, David, primary, Ong, Richard, primary, Soo, Khee Chee, primary, Pochanard, Panisa, primary, Yang, David, primary, Ruddy, David, primary, Liu, Manway, primary, Derti, Adnan, primary, Balak, Marissa N., primary, Palmer, Michael R., primary, Wang, Yan, primary, Lee, Benjamin H., primary, Sellami, Dalila, primary, Zhu, Andrew X., primary, Schlegel, Robert, primary, and Huang, Alan, primary

Published
2023
Full Text
View/download PDF

15. Data from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Author

Hao, Huai-Xiang, primary, Wang, Hongyun, primary, Liu, Chen, primary, Kovats, Steven, primary, Velazquez, Roberto, primary, Lu, Hengyu, primary, Pant, Bhavesh, primary, Shirley, Matthew, primary, Meyer, Matthew J., primary, Pu, Minying, primary, Lim, Joanne, primary, Fleming, Michael, primary, Alexander, LeighAnn, primary, Farsidjani, Ali, primary, LaMarche, Matthew J., primary, Moody, Susan, primary, Silver, Serena J., primary, Caponigro, Giordano, primary, Stuart, Darrin D., primary, Abrams, Tinya J., primary, Hammerman, Peter S., primary, Williams, Juliet, primary, Engelman, Jeffrey A., primary, Goldoni, Silvia, primary, and Mohseni, Morvarid, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Author

Huynh, Hung, primary, Hao, Huai-Xiang, primary, Chan, Stephen L., primary, Chen, David, primary, Ong, Richard, primary, Soo, Khee Chee, primary, Pochanard, Panisa, primary, Yang, David, primary, Ruddy, David, primary, Liu, Manway, primary, Derti, Adnan, primary, Balak, Marissa N., primary, Palmer, Michael R., primary, Wang, Yan, primary, Lee, Benjamin H., primary, Sellami, Dalila, primary, Zhu, Andrew X., primary, Schlegel, Robert, primary, and Huang, Alan, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 4 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 4 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Author

Huynh, Hung, primary, Hao, Huai-Xiang, primary, Chan, Stephen L., primary, Chen, David, primary, Ong, Richard, primary, Soo, Khee Chee, primary, Pochanard, Panisa, primary, Yang, David, primary, Ruddy, David, primary, Liu, Manway, primary, Derti, Adnan, primary, Balak, Marissa N., primary, Palmer, Michael R., primary, Wang, Yan, primary, Lee, Benjamin H., primary, Sellami, Dalila, primary, Zhu, Andrew X., primary, Schlegel, Robert, primary, and Huang, Alan, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 2 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Author

Huynh, Hung, primary, Hao, Huai-Xiang, primary, Chan, Stephen L., primary, Chen, David, primary, Ong, Richard, primary, Soo, Khee Chee, primary, Pochanard, Panisa, primary, Yang, David, primary, Ruddy, David, primary, Liu, Manway, primary, Derti, Adnan, primary, Balak, Marissa N., primary, Palmer, Michael R., primary, Wang, Yan, primary, Lee, Benjamin H., primary, Sellami, Dalila, primary, Zhu, Andrew X., primary, Schlegel, Robert, primary, and Huang, Alan, primary

Published
2023
Full Text
View/download PDF

20. Data from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Author

Huynh, Hung, primary, Hao, Huai-Xiang, primary, Chan, Stephen L., primary, Chen, David, primary, Ong, Richard, primary, Soo, Khee Chee, primary, Pochanard, Panisa, primary, Yang, David, primary, Ruddy, David, primary, Liu, Manway, primary, Derti, Adnan, primary, Balak, Marissa N., primary, Palmer, Michael R., primary, Wang, Yan, primary, Lee, Benjamin H., primary, Sellami, Dalila, primary, Zhu, Andrew X., primary, Schlegel, Robert, primary, and Huang, Alan, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 4 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Author

Huynh, Hung, primary, Hao, Huai-Xiang, primary, Chan, Stephen L., primary, Chen, David, primary, Ong, Richard, primary, Soo, Khee Chee, primary, Pochanard, Panisa, primary, Yang, David, primary, Ruddy, David, primary, Liu, Manway, primary, Derti, Adnan, primary, Balak, Marissa N., primary, Palmer, Michael R., primary, Wang, Yan, primary, Lee, Benjamin H., primary, Sellami, Dalila, primary, Zhu, Andrew X., primary, Schlegel, Robert, primary, and Huang, Alan, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Author

Hao, Huai-Xiang, primary, Wang, Hongyun, primary, Liu, Chen, primary, Kovats, Steven, primary, Velazquez, Roberto, primary, Lu, Hengyu, primary, Pant, Bhavesh, primary, Shirley, Matthew, primary, Meyer, Matthew J., primary, Pu, Minying, primary, Lim, Joanne, primary, Fleming, Michael, primary, Alexander, LeighAnn, primary, Farsidjani, Ali, primary, LaMarche, Matthew J., primary, Moody, Susan, primary, Silver, Serena J., primary, Caponigro, Giordano, primary, Stuart, Darrin D., primary, Abrams, Tinya J., primary, Hammerman, Peter S., primary, Williams, Juliet, primary, Engelman, Jeffrey A., primary, Goldoni, Silvia, primary, and Mohseni, Morvarid, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 5 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Author

Huynh, Hung, primary, Hao, Huai-Xiang, primary, Chan, Stephen L., primary, Chen, David, primary, Ong, Richard, primary, Soo, Khee Chee, primary, Pochanard, Panisa, primary, Yang, David, primary, Ruddy, David, primary, Liu, Manway, primary, Derti, Adnan, primary, Balak, Marissa N., primary, Palmer, Michael R., primary, Wang, Yan, primary, Lee, Benjamin H., primary, Sellami, Dalila, primary, Zhu, Andrew X., primary, Schlegel, Robert, primary, and Huang, Alan, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 5 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Author

Lu, Hengyu, primary, Liu, Chen, primary, Velazquez, Roberto, primary, Wang, Hongyun, primary, Dunkl, Lukas Manuel, primary, Kazic-Legueux, Malika, primary, Haberkorn, Anne, primary, Billy, Eric, primary, Manchado, Eusebio, primary, Brachmann, Saskia M., primary, Moody, Susan E., primary, Engelman, Jeffrey A., primary, Hammerman, Peter S., primary, Caponigro, Giordano, primary, Mohseni, Morvarid, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Tables from Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

Author

Baltschukat, Sabrina, primary, Engstler, Barbara Schacher, primary, Huang, Alan, primary, Hao, Huai-Xiang, primary, Tam, Angela, primary, Wang, Hui Qin, primary, Liang, Jinsheng, primary, DiMare, Matthew T., primary, Bhang, Hyo-Eun Carrie, primary, Wang, Youzhen, primary, Furet, Pascal, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Schoepfer, Joseph, primary, and Tiedt, Ralph, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 1 from Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Author

Liu, Chen, primary, Lu, Hengyu, primary, Wang, Hongyun, primary, Loo, Alice, primary, Zhang, Xiamei, primary, Yang, Guizhi, primary, Kowal, Colleen, primary, Delach, Scott, primary, Wang, Ye, primary, Goldoni, Silvia, primary, Hastings, William D., primary, Wong, Karrie, primary, Gao, Hui, primary, Meyer, Matthew J., primary, Moody, Susan E., primary, LaMarche, Matthew J., primary, Engelman, Jeffrey A., primary, Williams, Juliet A., primary, Hammerman, Peter S., primary, Abrams, Tinya J., primary, Mohseni, Morvarid, primary, Caponigro, Giordano, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 2 from Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Author

Liu, Chen, primary, Lu, Hengyu, primary, Wang, Hongyun, primary, Loo, Alice, primary, Zhang, Xiamei, primary, Yang, Guizhi, primary, Kowal, Colleen, primary, Delach, Scott, primary, Wang, Ye, primary, Goldoni, Silvia, primary, Hastings, William D., primary, Wong, Karrie, primary, Gao, Hui, primary, Meyer, Matthew J., primary, Moody, Susan E., primary, LaMarche, Matthew J., primary, Engelman, Jeffrey A., primary, Williams, Juliet A., primary, Hammerman, Peter S., primary, Abrams, Tinya J., primary, Mohseni, Morvarid, primary, Caponigro, Giordano, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 3 from Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Author

Liu, Chen, primary, Lu, Hengyu, primary, Wang, Hongyun, primary, Loo, Alice, primary, Zhang, Xiamei, primary, Yang, Guizhi, primary, Kowal, Colleen, primary, Delach, Scott, primary, Wang, Ye, primary, Goldoni, Silvia, primary, Hastings, William D., primary, Wong, Karrie, primary, Gao, Hui, primary, Meyer, Matthew J., primary, Moody, Susan E., primary, LaMarche, Matthew J., primary, Engelman, Jeffrey A., primary, Williams, Juliet A., primary, Hammerman, Peter S., primary, Abrams, Tinya J., primary, Mohseni, Morvarid, primary, Caponigro, Giordano, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Data from Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

Author

Baltschukat, Sabrina, primary, Engstler, Barbara Schacher, primary, Huang, Alan, primary, Hao, Huai-Xiang, primary, Tam, Angela, primary, Wang, Hui Qin, primary, Liang, Jinsheng, primary, DiMare, Matthew T., primary, Bhang, Hyo-Eun Carrie, primary, Wang, Youzhen, primary, Furet, Pascal, primary, Sellers, William R., primary, Hofmann, Francesco, primary, Schoepfer, Joseph, primary, and Tiedt, Ralph, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 1 from Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Author

Liu, Chen, primary, Lu, Hengyu, primary, Wang, Hongyun, primary, Loo, Alice, primary, Zhang, Xiamei, primary, Yang, Guizhi, primary, Kowal, Colleen, primary, Delach, Scott, primary, Wang, Ye, primary, Goldoni, Silvia, primary, Hastings, William D., primary, Wong, Karrie, primary, Gao, Hui, primary, Meyer, Matthew J., primary, Moody, Susan E., primary, LaMarche, Matthew J., primary, Engelman, Jeffrey A., primary, Williams, Juliet A., primary, Hammerman, Peter S., primary, Abrams, Tinya J., primary, Mohseni, Morvarid, primary, Caponigro, Giordano, primary, and Hao, Huai-Xiang, primary

Published
2023
Full Text
View/download PDF

43. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Author

Chen, Ying-Nan P., LaMarche, Matthew J., Chan, Ho Man, Fekkes, Peter, Garcia-Fortanet, Jorge, Acker, Michael G., Antonakos, Brandon, Chen, Christine Hiu-Tung, Chen, Zhouliang, Cooke, Vesselina G., Dobson, Jason R., Deng, Zhan, Fei, Feng, Firestone, Brant, Fodor, Michelle, Fridrich, Cary, Gao, Hui, Grunenfelder, Denise, Hao, Huai-Xiang, Jacob, Jaison, Ho, Samuel, Hsiao, Kathy, Kang, Zhao B., Karki, Rajesh, Kato, Mitsunori, Larrow, Jay, La Bonte, Laura R., Lenoir, Francois, Liu, Gang, Liu, Shumei, Majumdar, Dyuti, Meyer, Matthew J., Palermo, Mark, Perez, Lawrence, Pu, Minying, Price, Edmund, Quinn, Christopher, Shakya, Subarna, Shultz, Michael D., Slisz, Joanna, Venkatesan, Kavitha, Wang, Ping, Warmuth, Markus, Williams, Sarah, Yang, Guizhi, Yuan, Jing, Zhang, Ji-Hu, Zhu, Ping, Ramsey, Timothy, Keen, Nicholas J., Sellers, William R., Stams, Travis, and Fortin, Pascal D.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results